(Q57029642)

5

object named as

Bernd Jilma

0 references

author name string

Susanne Eder

1

0 references

Katrin Dubischar-Kastner

2

0 references

Christa Firbas

3

0 references

Tomas Jelinek

4

0 references

Astrid Kaltenboeck

6

0 references

Michael Knappik

7

0 references

Herwig Kollaritsch

8

0 references

Maria Paulke-Korinek

10

0 references

Elisabeth Schuller

11

0 references

Christoph S. Klade

Control of Japanese encephalitis--within our grasp?

12

0 references

language of work or name

English

0 references

publication date

March 2011

0 references

published in

Vaccine

0 references

volume

29

0 references

issue

14

0 references

page(s)

2607-2612

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Japanese Encephalitis Outbreak, India, 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine--a comparison of 1- and 3-month immunization schedules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Japanese encephalitis for a reference to international travelers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Booster vaccinations against tick-borne encephalitis: 6 years follow-up indicates long-term protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

An assessment of the interval between booster doses of Japanese encephalitis vaccine in the Torres Strait

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Yellow fever and Japanese encephalitis vaccines: indications and complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058

Adverse reactions to Japanese encephalitis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.01.058